Novozymes to supply Recombumin for diabetes drug
Signs exclusive agreement with ConjuChem in the US
Novozymes Biopharma of Nottingham, UK, a subsidiary of Danish firm Novozymes, has signed an agreement to supply ConjuChem of Los Angeles, California, US with its recombinant human albumin, Recombumin.
It will be used in the development of a new GLP-1 analog that is currently in Phase II testing for Type 2 diabetes.
Novozymes Biopharma says the use of Recombumin in the development of the product potentially reduces dosing frequency, allowing patients to self-inject once a week instead of once or twice daily.
Recombumin is the only commercially available, animal-free recombinant human albumin approved for use in human therapeutics. Manufactured to cGMP quality standards in large-scale facilities, the product is compliant with United States Pharmacopeia (USP) National Formulary (NF) standards.
